TirzepatideAlso known as: Mounjaro / Zepbound

Mechanism of Action

Tirzepatide is the first approved dual incretin agonist—it activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism provides advantages over GLP-1-only medications like semaglutide.

GLP-1 Receptor Effects

• Appetite suppression: Central effects on hypothalamic satiety centers
• Delayed gastric emptying: Prolongs feeling of fullness after meals
• Glucose-dependent insulin secretion: Increases insulin only when blood glucose is elevated
• Glucagon suppression: Reduces hepatic glucose output

GIP Receptor Effects

• Enhanced insulin secretion: Synergistic with GLP-1 effects
• Adipose tissue effects: May improve fat metabolism and distribution
• Bone metabolism: Potentially protective effects on bone density
• GI tolerability: May counteract some GLP-1-induced nausea

Clinical Evidence

SURMOUNT Trials (Obesity)

The SURMOUNT program established tirzepatide as the most effective weight loss medication:

• SURMOUNT-1: 22.5% weight loss at 15mg over 72 weeks (vs 2.4% placebo)
• SURMOUNT-2: 15.7% weight loss in patients with diabetes
• SURMOUNT-3: 26.6% total weight loss with intensive lifestyle intervention

SURPASS Trials (Diabetes)

For type 2 diabetes, tirzepatide demonstrated:

• Superior A1C reduction compared to semaglutide (SURPASS-2)
• Greater weight loss than any comparator studied
• High rates of diabetes remission (A1C <6.5% without medication)

Dosing Protocol

Standard Titration Schedule

Tirzepatide uses a slow titration to minimize GI side effects:

• Weeks 1-4: 2.5mg weekly
• Weeks 5-8: 5mg weekly
• Weeks 9-12: 7.5mg weekly
• Weeks 13-16: 10mg weekly
• Weeks 17-20: 12.5mg weekly
• Week 21+: 15mg weekly (maximum dose)

Administration

• Inject subcutaneously in abdomen, thigh, or upper arm
• Rotate injection sites weekly
• Same day each week (flexible timing)
• Can be taken with or without food

Side Effects and Management

Gastrointestinal (Most Common)

• Nausea: 20-30% incidence; usually improves over weeks 4-8
• Diarrhea: 15-20%; often transient
• Vomiting: 10-15%; worse with faster titration
• Constipation: 10-15%; from slowed GI motility

Management: Eat smaller meals, avoid fatty/greasy foods, stay hydrated, slow titration if needed. Most GI effects diminish with continued use.

Serious Risks

• Pancreatitis: Rare but serious; discontinue if suspected
• Gallbladder disease: Increased risk with rapid weight loss
• Hypoglycemia: Risk when combined with insulin or sulfonylureas

Tirzepatide vs Semaglutide

Head-to-head comparison based on clinical data:

Weight Loss

• Tirzepatide 15mg: ~22% average weight loss
• Semaglutide 2.4mg: ~15% average weight loss
• Winner: Tirzepatide (significant advantage)

Glycemic Control

• Tirzepatide: Greater A1C reduction
• Semaglutide: Excellent but slightly less than tirzepatide
• Winner: Tirzepatide (modest advantage)

Tolerability

• GI side effects: Similar incidence
• Some patients tolerate one better than the other
• Winner: Individual-dependent

Frequently Asked Questions

How much weight can you lose on tirzepatide?

Clinical trials showed average weight loss of 20-25% of body weight at the highest doses over 72 weeks. Individual results vary based on starting weight, dose achieved, diet, and exercise.

What is the difference between tirzepatide and semaglutide?

Tirzepatide is a dual GLP-1/GIP agonist, while semaglutide targets only GLP-1 receptors. Clinical data shows tirzepatide produces greater weight loss and glycemic control.

What is the tirzepatide dosing schedule?

Tirzepatide starts at 2.5mg weekly for 4 weeks, then increases by 2.5mg every 4 weeks as tolerated up to a maximum of 15mg weekly.

Do you regain weight after stopping tirzepatide?

Studies show significant weight regain (approximately 2/3 of lost weight) after discontinuation if lifestyle changes are not maintained. Long-term use or maintenance dosing may be necessary for sustained results.